A system and method for injecting an electron beam to an accelerator are provided. The system may include a cathode, an anode, and a modulation electrode. The cathode, for generating the electron beam, may have a first electrical potential. The anode may have a second electrical potential. The modulation electrode, located between the cathode and the anode, may be configured to adjust at least one parameter of the electron beam. The at least one parameter of the electron beam may include at least one transverse parameter of the electron beam.

A radiation medical device, including a main support, and a radiation assembly (30) and an imaging assembly (20) respectively located at both ends of the main support. After an imaging scan is completed and pathological tissue positioning pictures are taken, a patient is directly moved to the other end of the main support to allow the radiation assembly (30) to perform radiation therapy to improve the efficiency of the radiation therapy after the completion of pathological tissue positioning, and effectively reduce movement of the patient when the patient is being moved for radiation therapy after the imaging assembly (20) completes pathological tissue positioning, thus reducing pathological tissue positioning error caused by too much movement.

A particle beam radiotherapy system has been proposed by using a set of first and second scatterers, whereby a short-duration pulse beam is irradiated to a lesion. When the duration of the radiotherapy beam is 200 milliseconds or less, healthy tissues are selectively protected and only cancer tissues are damaged. For example, it can be used for cancer treatment of brain metastases that may be distributed throughout the entire brain tissues. The positions of the scatterers and the energy of the incident particle beams are optimized according to the position and the volume of the brain tissues.

A radiotherapy device is disclosed. The radiotherapy device includes a radiation source, a detecting means and controller communicatively coupled to the radiation source and the detecting means. The radiation source is configured to generate a treatment beam for irradiating a subject. The detecting means is configured to detect a motion of the subject, the motion comprising a first physiological motion component and a second physiological motion component. The controller is configured to generate a beam shaping control signal based on the first physiological motion component and to generate a beam gating control signal based on the second physiological motion component

Methods and systems for applying beta radiation and an anti-VEGF compound to a treatment area, such as a target area of a bleb, before, during, or after glaucoma surgery. The methods and systems herein may help reduce intraocular pressure, achieve and/or maintain a healthy intraocular pressure, maintain functioning blebs and/or drainage holes arising from glaucoma drainage procedures or surgeries, help avoid scar formation or wound reversion, inhibit or reduce fibrogenesis and/or inflammation in the blebs or surrounding areas, etc.

A radiotherapy dose rate monitor system includes an electrode configured to be impinged by radiotherapy radiation, and a current measurement circuit configured to measure a current through the electrode. An emission of secondary electrons emitted from the electrode provides a majority of current through the electrode.

A high-energy radiation treatment system can comprise a laser-driven accelerator system, a patient monitoring system, and a control system. The laser-driven accelerator system, such as a laser-driven plasma accelerator or a laser-driven dielectric microstructure accelerator, can be constructed to irradiate a patient disposed on a patient support. The patient monitoring system can be configured to detect and track a location or movement of a treatment volume within the patient. The control system can be configured to control the laser-driven accelerator system responsively to the location or movement of the treatment volume. The system can also include a beam control system, which generates a magnetic field that can affect the radiation beam and/or secondary electrons produced by the irradiation beam. In some embodiments, the beam control system and the patient monitoring system can comprise a magnetic resonance imaging system.

The present invention relates to radiation therapy. In order to improve the accuracy in deformable image registration in radiation therapy planning, a method is provided that comprises a) receiving a dose distribution to be delivered during one or more treatment sessions according to a radiation therapy plan, b) receiving contours delineating at least one region of interest, ROI, of at least one of the medical images, c) receiving one or more treatment objectives associated with the at least one ROI that has delineated contours, d) determining one or more critical regions in at least one of the medical images, where a geometric error of the contours of the at least one ROI and/or an uncertainty in the electron density distribution leads to a violation of one or more treatment objectives with respect to the dose distribution, and e) improving the accuracy of a deformable image registration algorithm in the one or more critical regions for registering the at least two medical images, wherein the deformable image registration algorithm estimates a deformation between the at least two medical images.

Described is a device for radiotherapy treatment with a high dose rate of ionizing radiation, comprising an accelerating guide (11) of a medical radiofrequency accelerator, at least two simultaneously thermostated resonant cavities (10) and comprising a first pick-up (12), a second pick-up (12B) in at least two resonant cavities (10) and an optical system (20) of the beam.

The present invention provides a radioactive patch comprising a layer of a mixture of a radionuclide with a nonreactive adhesive agent coated thereon in the form of a tape, and a laminating layer, wherein the patch comprises, a high Z shielding layer placed on the opposing side of the patch away from the patient tissue, and comprising at least one of: lead, tungsten, iron, silver, gold, platinum, copper, brass; and wherein the patch comprises, a low Z shielding layer comprising at least one of: teflon, pma, pvc, lucite, boron carbide, graphite, carbon fiber, bakelite; and wherein the radionuclide comprises at least one of: Y-90, Ho-166, LU-166, I-125, PD-103, LU-166, or any combination thereof.